- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 20-08-2025: Press Release
20-08-2025 | 10:13 am
20-08-2025 | 10:13 am
Lupin launched Bosentan Tablets for Oral Suspension in the US, gaining 180-day exclusivity. This drug, for pulmonary arterial hypertension, targets an estimated annual market of USD 1 Cr. Key revenue driver expected.
No comments yet. Be the first to comment!